- Home
- Publications
- Publication Search
- Publication Details
Title
The role of sulfonylureas in the treatment of type 2 diabetes
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 23, Issue 3, Pages 387-403
Publisher
Informa UK Limited
Online
2021-11-11
DOI
10.1080/14656566.2021.1999413
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis
- (2021) Jeong Yee et al. CLINICAL THERAPEUTICS
- Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
- (2021) Rita R. Kalyani NEW ENGLAND JOURNAL OF MEDICINE
- Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype
- (2021) Tanja Dujic et al. Journal of Personalized Medicine
- Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018
- (2021) Michael Fang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological and molecular docking studies reveal that glibenclamide competitively inhibits diazoxide-induced mitochondrial ATP-sensitive potassium channel activation and pharmacological preconditioning
- (2021) Plínio Bezerra Palácio et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY
- (2020) Alan J. Garber et al. Endocrine Practice
- Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives
- (2020) Kamlesh Khunti et al. Diabetes Therapy
- Latest Evidence on Sulfonylureas: What’s New?
- (2020) Lawrence A. Leiter Diabetes Therapy
- Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2020) Wendy K. Chung et al. DIABETES CARE
- Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel
- (2020) Agostino Consoli et al. DIABETES OBESITY & METABOLISM
- Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes
- (2020) Francesco Zaccardi et al. DIABETES OBESITY & METABOLISM
- Japanese Clinical Practice Guideline for Diabetes 2019
- (2020) Eiichi Araki et al. Journal of Diabetes Investigation
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
- (2020) Lorraine Lipscombe et al. Canadian Journal of Diabetes
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Standards of medical care for type 2 diabetes in China‐0027
- (2019) Weiping Jia et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: An international prospective study (DAR-MENA T2DM)
- (2019) Mohamed Hassanein et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2019) Priscilla Hollander et al. CURRENT MEDICAL RESEARCH AND OPINION
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Diabetes: Is there a future for Pharmacogenomics guided treatment?
- (2019) Ewan R Pearson CLINICAL PHARMACOLOGY & THERAPEUTICS
- Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride
- (2019) Elisabetta Patorno et al. DIABETES CARE
- Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
- (2019) John M Dennis et al. Lancet Diabetes & Endocrinology
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Identification of an ATP-sensitive potassium channel in mitochondria
- (2019) Angela Paggio et al. NATURE
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Drug–drug–gene interactions and adverse drug reactions
- (2019) Mustafa Adnan Malki et al. PHARMACOGENOMICS JOURNAL
- Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial
- (2018) Martin Ridderstråle et al. DIABETES OBESITY & METABOLISM
- The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
- (2018) Stephen Colagiuri et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial
- (2018) Wen-Huan Feng et al. Journal of Diabetes Investigation
- Do sulphonylureas still have a place in clinical practice?
- (2018) Kamlesh Khunti et al. Lancet Diabetes & Endocrinology
- Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study
- (2018) Pamela Bowman et al. Lancet Diabetes & Endocrinology
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
- (2018) Emma Ahlqvist et al. Lancet Diabetes & Endocrinology
- A Global Overview of Precision Medicine in Type 2 Diabetes
- (2018) Hugo Fitipaldi et al. DIABETES
- Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data
- (2018) John M. Dennis et al. DIABETES CARE
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses
- (2018) Alan Maloney et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genetics of Monogenic Diabetes: Present Clinical Challenges
- (2018) Shivani Misra et al. Current Diabetes Reports
- Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction? Or A Drug Class Worth Reviving?
- (2018) RLM Cordiner et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacotherapy of ‘treatment resistant’ type 2 diabetes
- (2017) André J. Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
- (2017) Olga Vaccaro et al. Lancet Diabetes & Endocrinology
- Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
- (2017) Priscilla Hollander et al. Diabetes Therapy
- Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
- (2017) Priscilla Hollander et al. Diabetes Therapy
- Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study
- (2016) Jil Mamza et al. ANNALS OF MEDICINE
- Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
- (2016) Steve Bain et al. DIABETES OBESITY & METABOLISM
- The University Group Diabetes Program 1961-1978: pioneering randomized controlled trial
- (2016) Henry Blackburn et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
- (2016) Dimitris Varvaki Rados et al. PLOS MEDICINE
- Is gliclazide a sulfonylurea with difference? A review in 2016
- (2016) Awadhesh Kumar Singh et al. Expert Review of Clinical Pharmacology
- Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents
- (2015) Siew Pheng Chan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Mortality risk among sulfonylureas: a systematic review and network meta-analysis
- (2015) Scot H Simpson et al. Lancet Diabetes & Endocrinology
- KCNJ11E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients
- (2014) Qing Li et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Sulfonylureas: A New Look at Old Therapy
- (2014) Peter M. Thulé et al. Current Diabetes Reports
- Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On!
- (2014) Saul Genuth DIABETES CARE
- Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes
- (2014) Sophia Zoungas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials
- (2014) Gijs W. D. Landman et al. PLoS One
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus
- (2013) Christianne L. Roumie et al. ANNALS OF INTERNAL MEDICINE
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
- (2013) J. A. Hirst et al. DIABETOLOGIA
- Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
- (2013) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Association betweenTCF7L2Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide
- (2013) Martin Javorský et al. International Journal of Endocrinology
- Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study
- (2012) S.R. Aravind et al. CURRENT MEDICAL RESEARCH AND OPINION
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- The Duration of Sulfonylurea Treatment Is Associated with β-Cell Dysfunction in Patients with Type 2 Diabetes Mellitus
- (2012) Mi-Seon Shin et al. Diabetes Technology & Therapeutics
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- The Molecular Genetics of Sulfonylurea Receptors in the Pathogenesis and Treatment of Insulin Secretory Disorders and Type 2 Diabetes
- (2011) Veronica Lang et al. Current Diabetes Reports
- The Cost-Effectiveness of Personalized Genetic Medicine: The case of genetic testing in neonatal diabetes
- (2011) S. A. W. Greeley et al. DIABETES CARE
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Variations in tissue selectivity amongst insulin secretagogues: a systematic review
- (2011) A. S. Abdelmoneim et al. DIABETES OBESITY & METABOLISM
- Heterozygous ABCC8 mutations are a cause of MODY
- (2011) P. Bowman et al. DIABETOLOGIA
- The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial
- (2011) S. Al Sifri et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A
- (2011) Veronica Y. Lang et al. Pharmacogenetics and Genomics
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes
- (2010) Z. Schroner et al. DIABETES OBESITY & METABOLISM
- Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.
- (2010) B. Gallwitz et al. DIABETES OBESITY & METABOLISM
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
- (2010) Olivia J. Phung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease
- (2009) M. F. Moen et al. Clinical Journal of the American Society of Nephrology
- Loss-of-Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go-DARTS Study
- (2009) K Zhou et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Intensive glucose control and macrovascular outcomes in type 2 diabetes
- (2009) F. M. Turnbull et al. DIABETOLOGIA
- Presence ofCYP2C9*3allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
- (2009) Georgia Ragia et al. PHARMACOGENOMICS
- The Sulfonylurea Receptor, an Atypical ATP-Binding Cassette Protein, and Its Regulation of the K ATP Channel
- (2008) Michael A. Burke et al. CIRCULATION RESEARCH
- Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients
- (2008) Y. Feng et al. DIABETES CARE
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic Antidiabetic Sulfonylureas In Vivo: Reversible Effects on Mouse Pancreatic β-Cells
- (2008) Maria Sara Remedi et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search